Skip to content

Leukemia & Lymphoma

Font Size
A
A
A

FDA Approves Imbruvica for Chronic Leukemia

Drug inhibits enzyme that spurs cancer growth

WebMD News from HealthDay

By Scott Roberts

HealthDay Reporter

WEDNESDAY, Feb. 12, 2014 (HealthDay News) -- U.S. Food and Drug Administration approval of Imbruvica (ibrutinib) has been expanded to include people with chronic lymphocytic leukemia (CLL) who have tried at least one other anti-cancer therapy.

CLL progresses slowly, gradually leading to an increase in white blood cells called B lymphocytes. Last year, some 15,680 Americans were diagnosed with CLL and 4,580 died from it, the agency said Wednesday in a news release, citing the National Cancer Institute.

Imbruvica was approved last November to treat people with mantle cell lymphoma.

Approval for CLL was based on clinical studies involving 48 people, the FDA said. Some 58 percent of participants had their cancer shrink after treatment.

Among the most common side effects of the drug were: low blood platelets, diarrhea, bruising, upper respiratory tract infection, fatigue and muscle pain.

Imbruvica is manufactured by Pharmacyclics, based in Sunnyvale, Calif.

Today on WebMD

stem cells
What are they and why do we need them?
Lung cancer xray
See it in pictures, plus read the facts.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Do you know the symptoms?
 
Vitamin D
SLIDESHOW
New Treatments For Non-Hodgkins Lymphoma
FEATURE
 
Lifestyle Tips for Depression Slideshow
SLIDESHOW
Pets Improve Your Health
SLIDESHOW